Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Dar Al Dawa Development and Investment Debt-to-Equity?
Dar Al Dawa Development and InvestmentAMM:DADI 75 Debt-to-Equity is 0.63 as of Jun. 2026, which is 35% below its 10-year median of 0.97. GuruFocus rates AMM:DADI with a GF Score™ of 75/100 and a GF Value™ of JOD1.03 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 814 Drug Manufacturers companies, Dar Al Dawa Development and Investment ranks worse than 76.78% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
AMM:DADI'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.97 Max: 2.38
Current: 0.63
During the past 13 years, the highest Debt-to-Equity Ratio of Dar Al Dawa Development and Investment was 2.38. The lowest was 0.06. And the median was 0.97.
AMM:DADI's Debt-to-Equity is ranked worse than 76.78% of 814
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs AMM:DADI: 0.63
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Dar Al Dawa Development and Investment Debt-to-Equity Related Terms
Dar Al Dawa Development and Investment Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment Debt-to-Equity Chart
Dar Al Dawa Development and Investment Annual Data
AMM:DADI vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Dar Al Dawa Development and Investment's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment (AMM:DADI) has a Debt-to-Equity of 0.63 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Dar Al Dawa Development and Investment and its competitors. This is 35% below median its historical median of 0.97. Over the past decade, Dar Al Dawa Development and Investment's Debt-to-Equity has ranged from 0.06 to 2.38. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #625 out of 814 companies in the Drug Manufacturers industry, placing it in the top 76.8%.
Is Dar Al Dawa Development and Investment's Debt-to-Equity too high?
Dar Al Dawa Development and Investment's current Debt-to-Equity of 0.63 is 35% below median its 10-year median of 0.97. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 2.38. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Dar Al Dawa Development and Investment's value of 0.63 is 129.1% above this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #625 out of 814 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #625 out of 814 companies for Debt-to-Equity. This places Dar Al Dawa Development and Investment in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Dar Al Dawa Development and Investment's value of 0.63 is 129.1% above this benchmark. Historically, Dar Al Dawa Development and Investment's own Debt-to-Equity has ranged from 0.06 to 2.38 over the past decade. While the company's 10-year median is 0.97 vs. the industry median of 0.28, Dar Al Dawa Development and Investment has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current Debt-to-Equity of 0.63 is 129.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current Debt-to-Equity is 0.63, which is 35% below median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD1.03, compared to a current price of JOD1.19 — trading 15.5% above its estimated fair value. The current Debt-to-Equity is 0.63, which is 35% below median its 10-year median of 0.97 and 129.1% above the Drug Manufacturers industry median of 0.28. Dar Al Dawa Development and Investment's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current Debt-to-Equity is 0.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.19 is trading 15.5% above its estimated GF Value™ of JOD1.03.
GuruFocus considers Dar Al Dawa Development and Investment to be Modestly Overvalued.
Key valuation signals for AMM:DADI:
Debt-to-Equity: 0.63 (35% below median its 10-year median of 0.97)
GF Value™: JOD1.03 vs. price of JOD1.19 (15.5% above fair value)
Industry Position: 129.1% above the Drug Manufacturers median (#625 of 814)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
75GF Score
Get the complete analysis for AMM:DADI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
